NEW MEMBER

NEWDIGS welcomes Cerevel Therapeutics as a new collaborator on the LEAPS Project

Collaboration to enhance the capacity of disease ecosystems for regimen optimization

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, is the latest company to join NEWDIGS’s expanding and diverse list of collaborators, which includes biopharmaceutical manufacturers, care providers, regulators, payers, health authorities, health technology assessment bodies, patient advocacy groups and other health care stakeholders. “Cerevel is an important and timely collaborator for the LEAPS project as we position ourselves to scale the concepts, platform strategies, tools and learnings beyond the initial target disease of Rheumatoid Arthritis and into other disease areas,” said Gigi Hirsch, MD, executive director of NEWDIGS. Read the announcement.

COMING UP

Diving into the Deep: Adaptive Point of Care Platforms

Heard about Master Protocols at a LEAPS Design Lab and want to learn more? Interested in learning about SMART study designs and how they are developed? Curious about platform strategies or how adaptive platform trials are transforming clinical trial research? 

Then you need to join us for the LEAPS Adaptive Point of Care (APoC) webinar series in March 2021! This two-part webinar will dive deep into the world of master protocols and adaptive platforms. Attendees will learn more about the LEAPS APoC Platform and its potential to improve patient outcomes by optimizing drug treatment regimens. Dr. Kay Larholt, Director of Research, MIT NEWDIGS and guest speakers with platform strategy expertise will provide attendees with a methodological foundation of these concepts, examples of real world implementation, and then expand into related topics, including endpoint concordance and biomarker validation. 

Who should attend? Outcomes Researchers, Biostatisticians, Designers and Implementers of pragmatic trials

What’s next? Webinar dates and times and registration details will be announced in mid-January. Stay tuned!